Not So Different: A Podcast from The Center for Biosimilars
Kanalinformation
Not So Different: A Podcast from The Center for Biosimilars
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
Seneste episoder
158 episoder
S7 Ep6: All Things Biosimilars: How Streamlined CES Rules Could Shift the Market
To learn more about the FDA draft guidance regarding clinical efficacy studies for biosimilars and interchangeability, click here.
To read more...
S7 Ep5: Follow the Science: Bridging the Biosimilar Gap
This special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part...
S7 Ep4: Escaping the Void: All Things Biosimilars With Craig & G
REFERENCE
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. htt...
S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
Show notes
To learn more about the 10th anniversary of the first FDA biosimilar approval, click here.
To learn more about how mu...
S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
Show notes
To learn more about the FTC's most recent report on PBMs, click here.
To learn more about the FTC's first report on PBMs, cl...
S7 Ep1: Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
Show notes1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed Februar...
S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024
Here are the top 5 episodes of Not So Different from 2024.
Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wy...
S6 Ep40: Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
Show Notes
1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. Nov...
S6 Ep39: Can Global Policies to Boost Biosimilar Adoption Work in the US?
Show notes
To learn more about GBW, click here.
To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here...
S6 Ep38: Biosimilars Development Roundup for October 2024—Podcast Edition
Show notes
1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. Octo...
S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition
Show notes
1. FDA Approves Pavblu for Retinal Conditions
2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part...
S6 Ep36: Biosimilars Business Roundup for August 2024—Podcast Edition
Show notes
1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024
2. Pure-Play Biosimilar Company Reports 10-Fold Reve...
S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition
Show notes
1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
S6 Ep34: Biosimilars in America: Overcoming Barriers and Maximizing Impact
Show notes
To learn more about Cencora and their efforts, click here.
To learn more about the Inflation Reduction Act's impact on biosimil...
S6 Ep33: Biosimilars Oncology Roundup for June 2024—Podcast Edition
Show notes
1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships
2. Overcoming Economic, Noneconomic Barr...
S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
To learn more about the approval of denosumab-bddz, click here.
To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteopo...
S6 Ep31: Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
Show notes
FDA Approves High-Concentration Cyltezo
Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimu...
S6 Ep30: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
Show notes
To read our coverage of the Cardinal Health report, click here.
To read the full report, click here.
To check out The Cen...
S6 Ep29: Biosimilars Policy Roundup for April 2024—Podcast Edition
Show notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
S6 Ep28: Biosimilars Dermatology Roundup for March 2024—Podcast Edition
Show notes
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
Posters From AMCCBS and AAD Showcase N...
S6 Ep27: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
Show notes
To read more of Ha Kung's thoughts on the US patent system and its role in the biosimilar landscape, click here.
To learn more...
S6 Ep26: Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
Show notes
FDA Approves 10th Adalimumab Biosimilar, Simlandi
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updat...
S6 Ep25: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
For more information on BsUFA III, click here.
For more information on the 1-year anniversary of adalimumab biosimilars in the US, click here.
S6 Ep24: Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
Happy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition
EMA Approves First Ustekinumab Biosimilar, Uzpruvo
E...
S6 Ep23: A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
Show notes
To learn more about the prospect for Neulasta OnPro biosimilars, click here.
To learn more about how the IRA will impact biosim...
S6 Ep22: The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
Show notes
To learn more about the FDA approval of Zymfentra, click here.
To learn more about the results from the LIBERTY trials, click h...
S6 Ep21: Biosimilar Oncology Roundup for November 2023—Podcast Edition
Show notes
Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
Part 1: Oncology Biosimilars Offer Comparable Benef...
S6 Ep20: Global Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews Future
Show notes
For more information on Global Biosimilars Week, click here.
To read our article series in honor of Global Biosimilars Week, yo...
S6 Ep19: Biosimilar Business Roundup for October 2023—Podcast Edition
FDA Approves First Subcutaneous Infliximab Product
Abrilada Approved as Second Interchangeable Humira Biosimilar
Eye on Phar...
S6 Ep18: Biosimilars Regulatory Roundup For September 2023– Podcast Edition
Show Notes
House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics
Part 2: FDA Workshop Shares Manufact...
S6 Ep17: Dr. Fran Gregory's Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
To read more about Dr. Gregory's commentary piece, click here.
To read more about Cardinal Health's 2023 Biosimilars Report, click here.
T...
S6 Ep16: Biosimilars Business Roundup For August 2023– Podcast Edition
Show Notes
FDA Approves First MS Biosimilar
Stelara and Enbrel Chosen for IRA Price Negotiation
Biocon Biosimil...
S6 Ep15: How Streamlining Development Can Save the US Biosimilar Industry
Show notes
To read CFB's analysis of the paper, click here.
To view the full version of the paper, click here.
To learn more...
S6 Ep14: Biosimilars Immunology Roundup for July 2023- Podcast Edition
Show Notes
First Round of Adalimumab Biosimilar Launches in July
Celltrion Launches Yuflyma on the US Market
US...
S6 Ep13: Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
Show notes
To learn more about the adalimumab products that have launched in the US so far, click here, here, here, or here.
Crohn's & Col...
S6 Ep12: Biosimilars Business Roundup for June 2023—Podcast Edition
Show notes
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
Roundup: Coherus Resolves Ab...
S6 Ep11: Biosimilars Immunology Roundup for May 2023—Podcast Edition
Show Notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3...
S6 Ep10: What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
To learn more about Tasmina's Asembia 2023 presentation, click here.
Check out the full AmerisourceBergen Biosimilar pipeline report.
To l...
S6 Ep9: Dr. Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Show notes
To read all the articles within the supplement, click here.
To read the article references in this episode, click here.
S6 Ep8: Biosimilars Rheumatology Roundup for April 2023—Podcast Edition
Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval
FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar
...